Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID-19 Encounter: A Retrospective Cohort Study From Alberta, Canada.

ABSTRACT:

Purpose

To describe the characteristics of adults who had a severe coronavirus disease 2019 (COVID-19) outcome during a timeframe that nirmatrelvir/ritonavir (NMV-r; Paxlovid) was available, to assess medical eligibility and receipt of NMV-r before presentation to acute care.

Methods

Population-level administrative data was used to describe adults (≥ 18 years) who had an acute care COVID-19 encounter (hospitalization or emergency department visit with COVID-19) between January 2022 and March 2023 in Alberta, Canada.

Results

The 30 793 adults had an acute care COVID-19 encounter; among the 8345 (27.1%) who were assessed as medically eligible for NMV-r, 8111 (97.2%) did not receive outpatient NMV-r ≤ 30 days before the encounter. During the acute care COVID-19 encounter

SUBMITTER: Aponte-Hao S 

PROVIDER: S-EPMC12741334 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature